Rosuvastatin in Older Patients with Systolic Heart Failure

John Kjekshus; Eduard Apetrei; Vivencio Barrios; Michael Böhm; John G.F. Cleland; Jan H. Cornel; Peter Dunselman; Cândida Fonseca; Assen Goudev; Peer Grande; Lars Gullestad; Åke Hjalmarson; J Hradec; András Jánosi; Gabriel Kamenský; Michel Komajda; J Korewicki; Timo Kuusi; François Mach; Mareev VIu; John J.V. McMurray; Naresh Ranjith; Maria Schaufelberger; Johan Vanhaecke; Dirk J. van Veldhuisen; Finn Waagstein; Hans Wedel; John Wikstrand

doi:10.1056/nejmoa0706201

Abstract

Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations. The drug did not cause safety problems. (ClinicalTrials.gov number, NCT00206310.)

Keywords

RosuvastatinMedicineHeart failureCardiologyInternal medicineRosuvastatin CalciumSystoleSystolic hypertensionBlood pressureDiastole

Related Publications

Heart failure with preserved left ventricular systolic function

Karen Hogg , Karl Swedberg , John J.V. McMurray

Recent cross-sectional, population-based echocardiographic studies show that about half of all patients with heart failure have preserved left ventricular systolic function (HF-...

2004 Journal of the American College of Ca... 933 citations

Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

Scott D. Solomon , John J.V. McMurray , Inder S. Anand +31 more

Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among patients with heart fail...

2019 New England Journal of Medicine 2159 citations

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Deepak L. Bhatt , Michael Szarek , Philippe Gabríel Steg +16 more

In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number ...

2020 New England Journal of Medicine 1698 citations

Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus

Clint Cushman , Gregory W. Evans , Robert P. Byington +10 more

In patients with type 2 diabetes at high risk for cardiovascular events, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, did no...

2010 New England Journal of Medicine 3530 citations

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

Faı̈ez Zannad , John J.V. McMurray , Henry Krum +6 more

Eplerenone, as compared with placebo, reduced both the risk of death and the risk of hospitalization among patients with systolic heart failure and mild symptoms. (Funded by Pfi...

2010 New England Journal of Medicine 2924 citations

Publication Info

Year: 2007
Type: article
Volume: 357
Issue: 22
Pages: 2248-2261
Citations: 1475
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Rosuvastatin in Older Patients with Systolic Heart Failure

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1475

OpenAlex

Cite This

APA Style

                            
                                
                                    John Kjekshus, 
                                
                                    Eduard Apetrei, 
                                
                                    Vivencio Barrios
                                
                                et al.
                            
                            (2007). 
                            Rosuvastatin in Older Patients with Systolic Heart Failure. 
                            New England Journal of Medicine
                            , 357
                            (22)
                            , 2248-2261.
                            https://doi.org/10.1056/nejmoa0706201
                        

Identifiers

DOI: 10.1056/nejmoa0706201